Milestone Pharmaceuticals (MIST) Long-Term Deferred Tax (2024 - 2025)
Milestone Pharmaceuticals' (MIST) quarterly Long-Term Deferred Tax came in at $83.3 million in Q4 2025, up 14.47% YoY from $72.8 million in Q4 2024, and up 14.47% on a QoQ basis from $72.8 million in Q4 2024.
Milestone Pharmaceuticals (MIST) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 2 years of Long-Term Deferred Tax data on file, last reported at $83.3 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 14.47% year-over-year to $83.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $83.3 million (up 14.47% YoY) and the FY2025 annual result came in at $83.3 million, up 14.47% from the prior year.
- Long-Term Deferred Tax climbed to $83.3 million in Q4 2025, from $72.8 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $83.3 million in Q4 2025 to a low of $72.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 83.31 Mn |
| Dec 31, 2024 | 72.78 Mn |